Developer docs
API playgroundTry for free, no card

Search company profiles

Codman Neuro

Full company profile

uuid002s4xq

Namestring
Codman Neuro
Legal namestring
Codman & Shurtleff
Websiteurl
codman.com
Company typeenum
Private
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRaynham, United States
HQ citystring
Raynham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neurosurgery medical devices, intracranial pressure monitoring, neurocritical care devices, hydrocephalus shunt systems, cerebrospinal fluid drainage
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Neurosurgery and Neurovascular Medical Devices
Social media profiles1 record
Cost components5 values
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Codman Neuro manufactures and sells specialty neurosurgery and neurovascular medical devices for hospitals and neurosurgical centers. Its core offerings include intracranial pressure (ICP) monitoring devices used in neurocritical care, hydrocephalus shunt valves and catheters, external cerebrospinal fluid (CSF) drainage systems, and complementary neurosurgical products such as dural repair grafts, CUSA tissue ablation, cranial reconstruction and stabilization, and electrosurgery devices. The company sells these products to neuro-ICUs, neurosurgery departments, and critical care units worldwide.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Codman Neuro products include intracranial pressure monitoring devices for neurocritical care applications. Based on market research data, Codman & Shurtleff is identified as a key player in the global intracranial pressure monitoring devices market, which was valued at USD 1.89 billion in 2025 and projected to reach USD 3.71 billion by 2035.

Product and service1 record
1Codman & Shurtleff Intracranial Pressure Monitoring Devices
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codman Neuro

Neurosurgery and Neurovascular Medical Devicescodman.com

Codman Neuro firmographics

Firmographics
Name
Codman Neuro
Legal name
Codman & Shurtleff
Website
https://codman.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Codman Neuro is headquartered

Location

Headquarters

HQ city
Raynham
HQ country
United States
HQ region
North America

Markets served

Codman Neuro business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales

Codman Neuro product offering

Product offering

Core offering

Codman Neuro manufactures and sells specialty neurosurgery and neurovascular medical devices for hospitals and neurosurgical centers. Its core offerings include intracranial pressure (ICP) monitoring devices used in neurocritical care, hydrocephalus shunt valves and catheters, external cerebrospinal fluid (CSF) drainage systems, and complementary neurosurgical products such as dural repair grafts, CUSA tissue ablation, cranial reconstruction and stabilization, and electrosurgery devices. The company sells these products to neuro-ICUs, neurosurgery departments, and critical care units worldwide.

Product overview

Codman Neuro products include intracranial pressure monitoring devices for neurocritical care applications. Based on market research data, Codman & Shurtleff is identified as a key player in the global intracranial pressure monitoring devices market, which was valued at USD 1.89 billion in 2025 and projected to reach USD 3.71 billion by 2035.

Differentiator

Problem solved

Functional benefit

Products and services

  • Codman & Shurtleff Intracranial Pressure Monitoring Devices

Companies that use Codman Neuro

Customer profile

Segments1 record

Ideal customer profiles1 record

Codman Neuro technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Codman Neuro partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves3 records

Expansion highlights3 records

Codman Neuro competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

Codman Neuro social profiles

Digital presence

Codman Neuro financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codman Neuro leadership team

Management profile

Number of profiles

Profiles1 record

Codman Neuro funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codman Neuro M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codman Neuro

What does Codman Neuro do?

Codman Neuro manufactures and sells specialty neurosurgery and neurovascular medical devices for hospitals and neurosurgical centers. Its core offerings include intracranial pressure (ICP) monitoring devices used in neurocritical care, hydrocephalus shunt valves and catheters, external cerebrospinal fluid (CSF) drainage systems, and complementary neurosurgical products such as dural repair grafts, CUSA tissue ablation, cranial reconstruction and stabilization, and electrosurgery devices. The company sells these products to neuro-ICUs, neurosurgery departments, and critical care units worldwide.

When was Codman Neuro founded?

Codman Neuro was founded in 2001. It employs 1 to 10 people.

Where is Codman Neuro based?

Codman Neuro is headquartered in Raynham, United States, in the North America region.

Does Codman Neuro have an API?

No public API is recorded for Codman Neuro.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNeurovascular Devices Market Size, Share & Trends Analysis Report By Therapeutic Applications, By Device, By Region And Segment Forecasts, 2020 - 2027This is a market research report covering the global neurovascular devices market, projecting it to reach USD 3.9 billion by 2027 with a compound annual growth rate of 5.6%. Growth is driven by rising demand for minimally invasive procedures, increasing incidence of neurological disorders such as stroke and brain aneurysm, and the introduction of technologically advanced products. The report identifies Medtronic, Microport Scientific Corporation, Penumbra Inc., Stryker, Johnson and Johnson Services Inc., Microvention Inc., and Codman Neuro as major players, with North America holding the largest market share in 2019.PR NewswireP. (Laxmin) Laxminarain Appointed to Millar's Board of DirectorsMillar, Inc. announced the appointment of P. (Laxmin) Laxminarain to its Board of Directors to leverage his extensive medical device industry experience for strategic growth. Laxminarain brings over 30 years of expertise, including previous leadership roles at Codman Neurosurgery and Cordis Cardiology under Johnson & Johnson.GlobeNewswireIntegra LifeSciences Completes the Acquisition of Codman Neurosurgery Business from Johnson & JohnsonIntegra LifeSciences completed its acquisition of Johnson & Johnson's Codman Neurosurgery business for approximately $1.045 billion. The deal expands Integra's neurosurgical portfolio, and it plans to sell certain assets, including the Camino ICP monitoring line, to Natus Medical pending regulatory reviews.GlobeNewswireNatus to Acquire Neurosurgery Assets from Integra LifeSciences, Enters Neurosurgery MarketNatus agreed to acquire neurosurgery assets from Integra LifeSciences for $47.5 million in cash, including the Camino ICP monitoring product line. The deal, contingent on Integra's Codman Neurosurgery acquisition, is expected to close in October 2017 and is expected to be immediately accretive to earnings.GlobeNewswireIntegra LifeSciences Reports First Quarter 2017 Financial ResultsIntegra LifeSciences reported first-quarter 2017 revenue of $258.6 million, up 9.2% year-over-year, with organic revenue up 6.4%. GAAP EPS was $0.08 and adjusted EPS was $0.39. The company maintained its full-year 2017 guidance and plans to complete the Codman Neurosurgery acquisition in the fourth quarter.PR NewswireCodman Neuro Announces Acquisition Of Neuravi Limited To Accelerate Innovation In Acute Ischemic Stroke TherapyCodman Neuro acquired Neuravi Limited, an Irish neurovascular therapy company, to accelerate acute ischemic stroke treatment. The EmboTrap device, used in over 3,000 European patients, has an FDA submission planned later this year. Financial terms were not disclosed.